BGPartner advises co-lead investors Forbion and Jeito Capital in USD 112 millions Series B financing round of Noema Pharma Ltd

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 millions (approx. USD 112 millions).

The round was co-led by the European healthcare focused investment firms Forbion and JEITO Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Inc., Gilde Healthcare and The Invus Group to complete the round.

The proceeds of the Series B financing will be used to advance Noema Pharma’s clinical-stage assets. Following the closing of this Series B financing round, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the board of directors of Noema Pharma Ltd.

BGPartner advised co-lead investors Forbion and Jeito Capital on all Swiss legal matters and the negotiations of this Series B financing round. The core team consisted of Oliver Gnehm (Partner) and Victoria Marty (Associate) and furthermore comprised Olivier Bula (Partner), Fabiola Weilenmann-Anthamatten (Managing Associate) and Geremia Stüssi (Jurist).

More information can be found here.